Insider Monkey's article reviews the stock market environment amid economic slowdown and high interest rates. Geron Corporation (NASDAQ:GERN) stands out as a top US stock under $5 due to its potential with Rytelo drug approval. The company's financial outlook remains positive despite mixed results.